• Explore /
  • Poster
  • / Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.

Abstract Video & Slides Poster

Authors

Hamid Emamekhoo

Hamid Emamekhoo

University of Wisconsin School of Medicine and Public Health, Madison, WI

Hamid Emamekhoo , Mark R Olsen , Bradley Curtis Carthon , Alexandra Drakaki , Ivor John Percent , Ana M. Molina , Daniel C. Cho , Johanna C. Bendell , Lucio N. Gordan , Arash Rezazadeh Kalebasty , Daniel J. George , Thomas E. Hutson , Edward Arrowsmith , Joshua Zhang , Jesus Zoco , Jennifer L. Johansen , David Leung , Scott S. Tykodi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02982954

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 4515)

DOI

10.1200/JCO.2021.39.15_suppl.4515

Abstract #

4515

Abstract Disclosures

Similar Posters

First Author: Hamid Emamekhoo

First Author: Thomas E. Hutson

First Author: Scott S. Tykodi

First Author: Dirk Schadendorf